NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapy Several clinical milestones expected over the next 12-18 months including updated data in pancreatic, and head and neck cancer, and initial data in esophageal and lung cancer €66.3 million in cash and cash equivalents as of June 30, 2024, with a cash runway extended into Q4 202 ...